Last reviewed · How we verify

Norvasc — Competitive Intelligence Brief

Norvasc (amlodipine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker (dihydropyridine). Area: Neuroscience.

marketed Calcium channel blocker (dihydropyridine) Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Norvasc (amlodipine) — Pfizer Inc.. Long-acting dihydropyridine calcium channel blocker that relaxes vascular smooth muscle, reducing blood pressure and myocardial oxygen demand.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Norvasc TARGET amlodipine Pfizer Inc. marketed Calcium channel blocker (dihydropyridine) Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6 1992-07-31
Amlodipin Amlodipin Boehringer Ingelheim marketed Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6
Nifedipine GITS (Adalat® XL 30 Nifedipine GITS (Adalat® XL 30 Shanghai Jiao Tong University School of Medicine marketed Calcium channel blocker (dihydropyridine) L-type calcium channel
Amlodipine+standard antihypertensive therapy Amlodipine+standard antihypertensive therapy Beijing Tiantan Hospital marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
Adalat (Nifedipine, BAYA1040) Adalat (Nifedipine, BAYA1040) Bayer marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
nifedipine controlled release tablets nifedipine controlled release tablets Guangzhou First People's Hospital marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
Amlodipine+intensive antihypertensive therapy Amlodipine+intensive antihypertensive therapy Beijing Tiantan Hospital marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker (dihydropyridine) class)

  1. Bayer · 2 drugs in this class
  2. Beijing Tiantan Hospital · 2 drugs in this class
  3. GlaxoSmithKline · 1 drug in this class
  4. Guangzhou First People's Hospital · 1 drug in this class
  5. Organon and Co · 1 drug in this class
  6. Peking University First Hospital · 1 drug in this class
  7. Pfizer Inc. · 1 drug in this class
  8. SK Chemicals Co., Ltd. · 1 drug in this class
  9. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
  10. Shanghai Shyndec Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Norvasc — Competitive Intelligence Brief. https://druglandscape.com/ci/amlodipine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: